This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willerson, J. T. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Willerson, J. T. Articles by Ridker, P. M.

(Circulation. 2004;109:II-2 – II-10.)
© 2004 American Heart Association, Inc.

Vascular Effects of Statins

Inflammation as a Cardiovascular Risk Factor

James T. Willerson, MD; Paul M. Ridker, MD, MPH

From the University of Texas Health Science Center and Texas Heart Institute at Houston (J.T.W.), University of Texas, Houston Medical School, Houston, Tex; and Harvard Medical School (P.M.R.), Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, Mass.

Correspondence to James T. Willerson, MD, Edward Randall III Professor and President, University of Texas, Houston Health Science Center, Houston, TX 77225. E-mail james.t.willerson{at}uth.tmc.edu

Abstract

Inflammation occurs in the vasculature as a response to injury, lipid peroxidation, and perhaps infection. Various risk factors, including hypertension, diabetes, and smoking, are amplified by the harmful effects of oxidized low-density–lipoprotein cholesterol, initiating a chronic inflammatory reaction, the result of which is a vulnerable plaque, prone to rupture and thrombosis. Epidemiological and clinical studies have shown strong and consistent relationships between markers of inflammation and risk of future cardiovascular events. Inflammation can potentially be detected locally by imaging techniques as well as emerging techniques, such as identification of temperature or pH heterogeneity. It can be detected systemically by measurement of inflammatory markers. Of these, the most reliable and accessible for clinical use is currently high-sensitivity C-reactive protein. A combination of methods may provide the best identification of persons at risk for cardiovascular events who would benefit from treatment. In randomized, controlled trials, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in the form of statins, have been shown to provide effective therapy for lowering CRP, in conjunction with their lipid-lowering effects. Although the magnitude of risk reduction associated with statin use appears to be largest for those with the highest serum levels of CRP, whether CRP reduction per se lowers cardiovascular risk is unknown.

Key Words: inflammation • C-reactive protein • local detection • systemic detection

This article has been cited by other articles:

				M. A. Mittleman A 39-year-old woman with hypercholesterolemia. JAMA, July 19, 2006; 296(3): 319 - 326. [Abstract] [Full Text] [PDF]

				J. P.H. van Wijk, E. J.P. de Koning, M. C. Cabezas, J. op't Roodt, J. Joven, T. J. Rabelink, and A. I. Hoepelman Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: A Randomized Trial Ann Intern Med, September 6, 2005; 143(5): 337 - 346. [Abstract] [Full Text] [PDF]

				E. J. Whitney, R. A. Krasuski, B. E. Personius, J. E. Michalek, A. M. Maranian, M. W. Kolasa, E. Monick, B. G. Brown, and A. M. Gotto Jr. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events Ann Intern Med, January 18, 2005; 142(2): 95 - 104. [Abstract] [Full Text] [PDF]